|Bid||0.3707 x 2200|
|Ask||0.3747 x 2200|
|Day's Range||0.3677 - 0.3967|
|52 Week Range||0.2800 - 7.0700|
|Beta (5Y Monthly)||1.05|
|PE Ratio (TTM)||1.26|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.33|
Endo (ENDP) collaborates with Taiwan Liposome to commercialize TLC599, an extended and controlled release liposomal formulated dexamethasone for chronic knee osteoarthritis (OA) pain.
TLC BioSciences has entered a commercialization agreement with Endo International plc (NASDAQ: ENDP) for the U.S. rights of TLC599, a proprietary BioSeizer sustained-release injectable in Phase 3 development for osteoarthritis pain. Under the agreement signed with Endo's subsidiary Endo Ventures Limited (EVL), TLC will primarily be responsible for developing the product, and EVL for obtaining regulatory approval and commercialization of the product in the U.S. TLC will receive an upfront payment
Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) has executed an agreement with Taiwan Liposome Company, Ltd. (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, to commercialize TLC599, a TLC investigational product. TLC599 is an injectable compound in Phase 3 development for the treatment of osteoarthritis knee pain.